Last reviewed · How we verify
Tovaxin Autologous T Cell Vaccine
Tovaxin Autologous T Cell Vaccine is a Biologic drug developed by Opexa Therapeutics, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Tovaxin Autologous T Cell Vaccine |
|---|---|
| Sponsor | Opexa Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (PHASE1, PHASE2)
- Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis (PHASE2)
- Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tovaxin Autologous T Cell Vaccine CI brief — competitive landscape report
- Tovaxin Autologous T Cell Vaccine updates RSS · CI watch RSS
- Opexa Therapeutics, Inc. portfolio CI
Frequently asked questions about Tovaxin Autologous T Cell Vaccine
What is Tovaxin Autologous T Cell Vaccine?
Tovaxin Autologous T Cell Vaccine is a Biologic drug developed by Opexa Therapeutics, Inc..
Who makes Tovaxin Autologous T Cell Vaccine?
Tovaxin Autologous T Cell Vaccine is developed by Opexa Therapeutics, Inc. (see full Opexa Therapeutics, Inc. pipeline at /company/opexa-therapeutics-inc).
What development phase is Tovaxin Autologous T Cell Vaccine in?
Tovaxin Autologous T Cell Vaccine is in Phase 2.
Related
- Manufacturer: Opexa Therapeutics, Inc. — full pipeline